Corpus Intelligence IC Memo — COVINGTON AMG REHABILITATION HOSPITA 2026-04-26 09:38 UTC
IC Memo — COVINGTON AMG REHABILITATION HOSPITA
Investment Committee Memorandum | LA | 24 beds | Grade D | EBITDA uplift $582K
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

COVINGTON AMG REHABILITATION HOSPITA

CCN 193097 | ST. TAMMANY PARISH, LA | 24 beds | April 26, 2026
EBITDA BridgeData Room
D
Investability

1. Target Overview & Investment Thesis

COVINGTON AMG REHABILITATION HOSPITA is a 24-bed rural/critical access in ST. TAMMANY PARISH, LA with $7.8M in net patient revenue and a 4.1% operating margin. The hospital serves a payer mix of 69.9% Medicare, 2.8% Medicaid, and 27.3% commercial.

Thesis: Turnaround. Our ML models identify $582K in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from 4.1% to 11.6% (+747bps).

Net Revenue HCRIS$7.8M
Current EBITDA COMPUTED$318K
Operating Margin COMPUTED4.1%
Occupancy HCRIS60.6%
Revenue / Bed COMPUTED$324K
Net-to-Gross HCRIS62.6%
Distress Probability ML51.8%

2. Market Context & Competitive Position

212
LA Hospitals
-3.5%
State Median Margin
129
Comparable Hospitals

LA has 212 Medicare-certified hospitals with a median operating margin of -3.5%. The target's margin of 4.1% places it above the state median. Among 129 size-comparable peers (12-48 beds), the median margin is -2.3%. The target performs in line with or above peers.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (12-48), prioritizing same-state peers. 129 hospitals in the comp set.

HospitalStateBedsRevenueMargin
COVINGTON AMG REHABILITATION H (Target)LA24$7.8M4.1%
SPECIALISTS HOSPITAL OF SHREVELA15$79.1M21.3%
OCHSNER BAYOU LLCLA25$76.5M-0.9%
OUR LADY OF THE ANGELS HOSPITALA36$76.2M-4.9%
CENTRAL LOUISIANA SURGICAL HOSLA24$69.1M7.7%
ABBEVILLE GENERAL HOSPITALLA44$68.5M3.4%
ST. CHARLES PARISH HOSPITALLA27$64.0M-5.1%
AVALALA21$64.0M7.4%
BYRD REGIONAL HOSPITALLA39$61.1M2.5%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $582K (747bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$164K+210bp18mo
Denial Rate Reduction12.0%6.5%$158K+203bp12mo
Cost to Collect4.5%2.5%$156K+200bp12mo
A/R Days Reduction5200.0%3800.0%$95K+122bp9mo
Clean Claim Rate88.0%96.0%$10K+12bp6mo

5. EBITDA Bridge

Net Collection Rate
$164K
Denial Rate Reduction
$158K
Cost to Collect
$156K
A/R Days Reduction
$95K
Clean Claim Rate
$10K
Total EBITDA Uplift$582K
Current EBITDA$318K
+ RCM Uplift+$582K
Pro Forma EBITDA$900K
Current Margin4.1%
Pro Forma Margin11.6%
WC Released (1x)$299K

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$489K$7.9M16.19x74.5%
Base (11x exit)10.0x11.0x$489K$8.9M18.13x78.5%
Bull Case9.0x11.0x$440K$10.9M24.87x90.2%
Bull (12x exit)9.0x12.0x$440K$12.1M27.43x93.9%
Bear Case11.0x10.0x$538K$4.8M9.01x55.2%
Bear (11x exit)11.0x11.0x$538K$5.5M10.24x59.2%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
MediumHeavy Medicare dependenceMedicare comprises 69.9% of days; rate updates may lag inflation. Mitigant: CDI/CMI lever directly increases Medicare reimbursement
HighElevated distress probabilityModel estimates 51.8% probability of financial distress. Mitigant: distressed entry pricing (7-9x) compensates for risk

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 129 hospitals with 12-48 beds
  • Same-state prioritization (n=130)
  • Comp margins: P25=-15.0% / P50=-2.3% / P75=6.4%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.